Radiation and immunotherapy with or without probiotics for advanced digestive cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding a probiotic (Lactobacillus rhamnosus M9) to standard radiation and immunotherapy can help people with advanced digestive system cancers. It aims to see if the combination is more effective and safer than the standard approach alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer of the stomach, liver, bile ducts, colon, or rectum that has spread and cannot be removed with surgery.
- You have not had any prior treatment for your advanced cancer (first-line treatment).
- You are between 18 and 75 years old.
- You are in good general health (able to care for yourself, ECOG score 0 or 1).
- You do not have certain serious heart conditions, active infections, or other cancers within the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests adding an immunotherapy drug (tislelizumab) and a probiotic to standard chemoradiation for locally advanced rectal cancer that has not spread. The goal is to see if the probiotic helps the treatment work better.
This trial tests whether adding a probiotic (Lactobacillus Johnsonii) to standard chemotherapy and immunotherapy can help people with certain advanced solid tumors that have stopped responding to prior immunotherapy. It may help your immune system work better against the cancer.
This trial tests a combination of a probiotic (Lactobacillus johnsonii), two chemotherapy drugs (CapeOX), and an immunotherapy (pembrolizumab) for people with a specific type of advanced colorectal cancer that has not responded to previous treatments. It aims to see if this mix can help control the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.